Aktiviteterne i forbindelse med lægemiddelovervågning, kommunikationsnettenes drift og markedsovervågning skal være under bestyrelsens stadige kontrol for at sikre agenturets uafhængighed.
Activities relating to pharmacovigilance, to the operation of communications networks and to market surveillance shall be under the permanent control of the Management Board in order to guarantee the independence of the Agency.